You just read:

Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis

News provided by

Glenmark Pharmaceuticals

29 Mar, 2017, 10:28 ET